Ph.D., Vice President, Head of Oncology Early Development, AbbVie
Dr. Mohit Trikha is Vice President, Head of Oncology Early Development at AbbVie. He is responsible for implementing the strategic vision for AbbVie’s Oncology Early Development pipeline through clinical proof of concept. Dr. Trikha has >20 years of drug discovery and development experience. Prior to joining AbbVie, he was President, CSO and Head of Triphase Accelerator and a Board member of Triphase Accelerator. He was the Chair of Triphase-Celgene Joint Steering Committee and prior to that he worked at Ambit, Genentech and Centocor/Johnson and Johnson. He is currently is on the Board of EnCycle Therapeutics as an independent member. Dr. Trikha is passionate about advancing first or best in class oncology medicines. His background is in cell signaling, tumor immunology, apoptosis, protein homeostasis, neuroscience, and developing biomarkers for predicting response and toxicity. He has published >40 papers, filed multiple patents and presented at AACR, ASCO, ASH, and EHA. He received his PhD from University of Southern California and was an Assistant Professor of Research at Wayne State University prior to joining the pharmaceutical industry
Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: This session will highlight a new model where science-based established and emerging companies can partner with an ever wider array of patients and with ever more differentiated personalized situations to advance care, scientific knowledge, and business success.